Envestnet Portfolio Solutions Inc. Cuts Stock Holdings in Zoetis Inc. $ZTS

Envestnet Portfolio Solutions Inc. cut its position in shares of Zoetis Inc. (NYSE:ZTS) by 25.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 50,495 shares of the company’s stock after selling 16,953 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Zoetis were worth $7,388,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Norges Bank purchased a new stake in shares of Zoetis during the 2nd quarter worth about $809,491,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Zoetis by 113.0% in the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 3,761,920 shares of the company’s stock valued at $586,671,000 after purchasing an additional 1,995,491 shares during the period. Corient Private Wealth LLC increased its position in shares of Zoetis by 85.9% in the second quarter. Corient Private Wealth LLC now owns 2,578,593 shares of the company’s stock valued at $400,619,000 after buying an additional 1,191,840 shares in the last quarter. Impax Asset Management Group plc raised its stake in shares of Zoetis by 362.6% during the 2nd quarter. Impax Asset Management Group plc now owns 1,176,996 shares of the company’s stock worth $182,705,000 after buying an additional 922,589 shares during the period. Finally, Swedbank AB lifted its position in shares of Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after buying an additional 917,598 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Several market write-ups argue Zoetis is undervalued after a roughly 24% one-year pullback and present a buying opportunity; these narratives can attract value-focused investors. Is Zoetis (ZTS) Offering An Opportunity After A 24% One-Year Share Price Pullback
• Positive Sentiment: A Seeking Alpha piece makes a case that Zoetis is “Undervalued And Oversold,” reinforcing the narrative that current levels could be attractive to long-term investors. Zoetis: Undervalued And Oversold
• Positive Sentiment: Wall Street Zen upgraded Zoetis to a “Buy,” which can provide short-term support as some investors chase analyst upgrades. Zoetis (NYSE:ZTS) Upgraded by Wall Street Zen to “Buy” Rating
• Neutral Sentiment: A roundup of eight analyst ratings shows mixed views across the street, indicating no clear consensus and contributing to stock volatility. 7ZTS : What 8 Analyst Ratings Have To Say About Zoetis
• Neutral Sentiment: Aggregated analyst consensus remains around a “Hold,” which suggests many pros see limited near-term upside absent clearer catalysts. Zoetis Inc. (NYSE:ZTS) Given Average Recommendation of “Hold” by Analysts
• Negative Sentiment: Piper Sandler downgraded ZTS from “Overweight” to “Neutral” and cut its price target sharply (from $190 to $135), a material change that likely pressured the stock and investor sentiment. Piper Sandler downgrades Zoetis (ZTS)

Wall Street Analysts Forecast Growth

Several brokerages recently commented on ZTS. JPMorgan Chase & Co. cut their price target on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a report on Wednesday, November 5th. UBS Group dropped their target price on shares of Zoetis from $158.00 to $141.00 and set a “neutral” rating on the stock in a research report on Wednesday, November 5th. Bank of America downgraded shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target for the company. in a research report on Monday, December 15th. Wall Street Zen raised shares of Zoetis from a “hold” rating to a “buy” rating in a research note on Friday. Finally, KeyCorp began coverage on Zoetis in a research note on Thursday, November 20th. They set a “sector weight” rating for the company. Five analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average price target of $152.91.

Zoetis Stock Down 0.3%

ZTS stock opened at $124.04 on Friday. The company has a market cap of $54.66 billion, a price-to-earnings ratio of 20.88, a PEG ratio of 2.15 and a beta of 0.97. The company has a current ratio of 3.64, a quick ratio of 2.28 and a debt-to-equity ratio of 1.31. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.40. The firm has a 50-day moving average of $123.58 and a two-hundred day moving average of $138.29.

Zoetis (NYSE:ZTS) last issued its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a return on equity of 57.19% and a net margin of 28.21%.The business’s revenue for the quarter was up .5% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.58 EPS. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This is an increase from Zoetis’s previous quarterly dividend of $0.50. This represents a $2.12 annualized dividend and a yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is 35.69%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.